《瑞信窝轮》里康季绩中药倒跌，留意里康购14999、中药购19089
阿里健康（0241）周二公布业绩，绩前靠稳，於22元附近前争持。看好可留意里康购14999，行使价26.28元，21年9月到期。或里康牛50252，收回价19.68元，行使价19.08元，21年7月到期。相反看淡可留意里康熊62317，收回价23.28元，行使价23.88元，21年10月到期。
中国生物制药（1177）首季多赚近1.2倍，周二高位曾急升逾7%，但高见9.69元後倒跌，低位曾挫逾4%至8.7元以下。观望反弹，可考虑中药购19089，行使价10.00元，21年12月到期。
微盟（2013）折让配股兼发可转换债券，微盟周二曾挫逾3%，低位企稳配股价，其後逐步回稳，重返16元以上。看好可留意微盟购25699，行使价17.77元，21年11月到期。或微盟牛61790，收回价13.88元，行使价13.38元，22年4月到期。
有报道指，北京对校外培训机构推三不政策，忧虑加强对教育行业监管，教育股新东方（9901）周二曾急泻超过15%，创出70.8元的上市新低。观望反弹，可留意新教购11439，行使价101.88元，21年12月到期。
以上产品资料来源: 彭博资讯及瑞信网站cswarrants.com
(本结构性产品并无抵押品)
《瑞信香港认股证及牛熊证销售主管何启聪》
免责声明：笔者为瑞士信贷(香港)有限公司的代表 ，并身为证监会持牌人，并无持有相关上市公司的任何财务权益。本文内容仅供参考，并不构成要约、建议或促使任何人士提呈买卖或认购任何证券。结构性产品价格可急升或急跌，投资者或会蒙受全盘损失。本产品并无抵押品。如发行人无力偿债或违约，投资者可能无法收回部份或全部应收款项。牛熊证备强制赎回机制而可能被提早终止，届时(i)N类牛熊证投资者将不获发任何金额；而(ii)R类牛熊证之剩余价值可能为零。有关恒生指数，恒生中国企业指数或恒生科技指数的免责声明，请参阅上市文件。有关纳斯达克100指数的免责声明，请参阅上市文件。过往表现并不反映将来表现。投资前，投资者应了解风险，并谘询专业顾问及查阅有关上市文件。瑞信之联属公司Credit Suisse Securities (Hong Kong) Limited为结构性产品之流通量提供者，亦可能是唯一报价者。本文任何内容概不构成投资、法律、会计或税务意见、并无声明任何投资或策略适合或符合阁下的个别情况。结构性产品交投量并不是结构性产品表现的指标，投资者不应仅依赖交投量历史高位数据以厘定结构性产品日後的表现。~
重要声明:
以上资讯由第三方提供，AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告，不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料，本公司亦不负品质保证之责任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
